Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy

Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy

(2019) Alex Molassiotis et al.   BMC CANCER

Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients

(2018) Alexandre Chan et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials

(2018) Ellen M. Lavoie Smith et al.   Cancer Control

Minimal Clinically Important Differences and Substantial Clinical Benefit in Patient-Reported Outcome Measures after Autologous Chondrocyte Implantation

(2018) Takahiro Ogura et al.   Cartilage

Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey

(2017) J . Matt McCrary et al.   SUPPORTIVE CARE IN CANCER

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

(2017) Hana Starobova et al.   Frontiers in Molecular Neuroscience

Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device

(2016) Ayumu Matsuoka et al.   CANCER SCIENCE

Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

(2016) Massimo Di Maio et al.   Nature Reviews Clinical Oncology

Minimally important difference estimates and methods: a protocol

(2015) Bradley C Johnston et al.   BMJ Open

Patient-reported outcomes in clinical practice

(2015) S. Dobrozsi et al.   Hematology-American Society of Hematology Education Program

Assessment of chemotherapy-induced peripheral neuropathy using the LDIFLAREtechnique: a novel technique to detect neural small fiber dysfunction

(2015) Sanjeev Sharma et al.   Brain and Behavior

Chemotherapy-induced neuropathy: A comprehensive survey

(2014) N.C. Miltenburg et al.   CANCER TREATMENT REVIEWS

Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients

(2014) Yin Ting Cheung et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Management options for established chemotherapy-induced peripheral neuropathy

(2014) Deirdre R. Pachman et al.   SUPPORTIVE CARE IN CANCER

Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature

(2014) Andreas Argyriou et al.   Cancer Management and Research

Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire

(2013) Ellen M. Lavoie Smith et al.   QUALITY OF LIFE RESEARCH

The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings

(2012) G. Cavaletti et al.   ANNALS OF ONCOLOGY

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes

(2007) Dennis Revicki et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY